Claim Your Author Page
BACKGROUND. Comprehensive genomic profiling of a patient's cancer can be used to diagnose, monitor, and recommend treatment. Clinical implementation of tumor profiling in an enterprise-wide,… (More)
Purpose:MET exon 14 deletion (METex14 del) mutations represent a novel class of non-small cell lung cancer (NSCLC) driver mutations. We evaluated glesatinib, a spectrum-selective MET inhibitor… (More)
Background: This phase II study evaluated the efficacy and safety/tolerability of sunitinib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC). Methods: Eligible patients… (More)
TPS9099Background: MGCD265 is an oral, potent, small molecule RTK inhibitor of MET and Axl, which are important for mediating signals for cell growth, survival, and migration. MET mutations and/or ...
2589 Background: MGCD265 is a spectrum-selective and ATP-competitive inhibitor with MET and Axl as clinically relevant RTK targets. In nonclinical studies, MGCD265 demonstrated anti-tumor activity in… (More)
8108 Background: PROFILE 1007 compared the efficacy and safety of the ALK inhibitor crizotinib (N=172) with that of standard-of-care chemotherapy (pemetrexed [PEM; N=99] or docetaxel [DOC; N=72]) in… (More)
8105 Background: PROFILE 1007 compared the efficacy and safety of crizotinib with that of standard-of-care chemotherapy in patients with ALK+ NSCLC. Although the study was not designed for formal… (More)
e14087Background: MGCD265 is an ATP-competitive inhibitor of MET and Axl RTKs and has demonstrated anti-tumor activity in xenograft cancer models of MET or Axl dysregulation and in Phase 1 clinical...